By effectively stimulating the endogenous release of growth hormone, CJC-1295 leads to increased levels of insulin-like growth factor I (IGF-I), a crucial mediator of growth and metabolic processes. The prolonged action of CJC-1295 means that it can be dosed less frequently compared to traditional GHRH therapies, which require daily injections due to their short-lived effects.

Research indicates that CJC-1295 may be beneficial in addressing age-related declines in growth hormone levels, potentially improving metabolic function and overall well-being. Its innovative design showcases the effectiveness of bioconjugation techniques in developing more effective peptide-based therapies. Overall, CJC-1295 with DAC is recognized for its capacity to enhance growth hormone secretion, providing a sustained physiological impact.